CONSEJERIA DE SALUD DE LA JUNTA DE ANDALUCIA [ CSJA ]

AVDA. AMERICO VESPUCIO -2 PLANTA 41092 SEVILLA - Spain

Involved in the following projects during the 3rd programme

3rd Health Programme (2014-2020)
Managing Frailty. A comprehensive approach to promote a disability-free advanced age in Europe: the ADVANTAGE initiative [ADVANTAGE]
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on...
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on which to base a common management approach of older people who are frail or at risk for developing frailty in the European Union.
The identification of the core components of frailty and its management should promote the needed changes in the organization and the implementation of the Health and Social Systems to provide those models of care that, stemming from the particular health profile of each Member State (MS), will allow them to face the challenge of frailty within a common framework.
ADVANTAGE will summarise the current State of the Art for the different components of frailty and its management, both at individual and population level, will collect information on the development of programs to manage frailty in older adults in the EU and will propose, as its main outcome, a common European model to approach frailty. This model will include a road map that, considering the degree of frailty policies� development, will propose interventions for frail and at risk people and will establish tailored milestones for each MS in order to achieve a comprehensive approach to promote a disability-free advanced age. Furthermore, the model will identify gaps of knowledge in the field that would benefit from further research.
Start date: 01/01/2017 - End date: 31/12/2019
Keywords : [ Ageing ] [ Frailty ] [ Function ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Prevention of frailty
3rd Health Programme (2014-2020)
Evidence-Based Guidance to Scale-up Integrated Care in Europe [VIGOUR]
VIGOUR will effectively support care authorities in progressing the transformation of their health and care systems to provide sustainable models for integrated care which will facilitate identificati...
VIGOUR will effectively support care authorities in progressing the transformation of their health and care systems to provide sustainable models for integrated care which will facilitate identification of good practice and scaling-up. This will be achieved through the delivery of an evidence-based integrated care support programme designed to understand and guide 16 care authorities through a staged process of analysis, advice on good practice and training in care system capacity and capability building and implementation approaches at the operational, organisational and strategic levels of stakeholders involved in different localities throughout Europe. In practice, care authorities will be supported in focussing their care integration ambitions, in operationally preparing the implementation of good practice suitably aligned to any prevailing local circumstances, and finally in rolling out these practices to at least one percent of their overall target population in the framework of local scaling-up projects as an integral part of project plans. Knowledge exchange and mutual learning throughout this process will be enhanced by a twinning scheme bringing together VIGOUR “pioneer” care authorities with “followers”. Further care authorities will benefit from the experiences gained by the VIGOUR participants throughout the staged scaling-up process in terms of dedicated webinar and podcast programmes.
Start date: 01/01/2019 - End date: 30/06/2022

Call: Call for Proposals for Projects 2018
Topic: Scaling up integrated care
3rd Health Programme (2014-2020)
European Network for Health Technology Assessment (EUnetHTA) - Joint Action 3 [EUnetHTA JA3]
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and...
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and health technologies and ensure re-use in regional and national HTA reports and activities, in order notably to avoid duplication of assessments. An overarching objective is to develop a general strategy, principles and proposal for a scientific and technical mechanism of permanent sustainable European Collaboration on HTA in the light of the Directive on CBHC. During the JA3 the collaborative production of structured HTA core information, including rapid HTAs will be structurally implemented and the methodologies and production related information and communication technology infrastructure will be finalised as to stand alone from 2020 onwards. EUnetHTA JA3 will also aim to increase the alignment between HTA reports used for reimbursement decisions and clinical practice guidelines that are used by physicians in daily practice. Additionally, EUnetHTA JA3 will also support more alignment of different processes in the lifecycle of health technologies. For instance, processes on market authorization and HTA of pharmaceuticals could be organised in a more closely aligned fashion which may lead to a timelier and more efficient process promoting earlier patient access to products that have a real added value. EUnetHTA JA3 will also contribute to the discussion on the assessment of the effectiveness and safety of new medical devices as is currently taken place as part of the debate on new European legislation for medical devices. Finally, all these outcomes will contribute to the dissemination of health information and knowledge, thus improving policy-and decision-making in the health systems, which turns into protection of citizens against unsafe or ineffective technologies and improves access to high value health technologies. Ultimately this contributes to imTo be developed
Start date: 01/06/2016 - End date: 31/05/2021

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Health Technology Assessment cooperation
3rd Health Programme (2014-2020)
CHRODIS-PLUS: Implementing good practices for chronic diseases [CHRODIS-PLUS]
Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion € or 0.8% of GDP annually; and this figure does not include the additional loss ...
Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion € or 0.8% of GDP annually; and this figure does not include the additional loss in terms of lower employment rates and productivity of people living with chronic health problems. However, the aspiration is a health-promoting Europe, free of preventable CD, premature death and avoidable disability could be possible. Initiatives on CD should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of CD; patient empowerment; tackling functional decline and quality of life as the main consequences of CD, and making health systems sustainable and responsive to the aging of our populations associated with the epidemiological transition (an increase in incidence of CD and extended life expectancy) whose consequence is an increasing prevalence of CD. In this Joint Action, CHRODIS-PLUS, our goal is to support Member States through cross-national initiatives identified in JA-CHRODIS to reduce the burden of CD, while assuring health systems sustainability and responsiveness. CHRODIS-PLUS aims to promote the implementation of policies and practices with demonstrated success in each of the four cornerstones mentioned, in closely monitored implementation experiences that can be validated before scaling them up. For this, a total of 42 beneficiaries representing 20 European countries will collaborate to implement pilots and generate practical lessons that could contribute to the uptake and use of CHRODIS-PLUS results. Practices to be implemented will be based on the collection of policies, strategies and interventions that started in JA-CHRODIS and in its outputs such as the Integrated Multimorbidity Care Model or the Recommendations for Diabetes Quality criteria or national plans. During the 36-month life CHRODIS-PLUS will disseminate its activities and monitor and evaluate them to verify the progress and impact of the action. CHRODIS-PLUS will look for synergies with international/regional/local policy initiatives in CD. CHRODIS-PLUS will count on the Governing Board of representatives from European Ministries of Health, key to CHRODIS-PLUS development and sustainability, an Executive Board and a General Assembly where all associated partners will gather. A proposal for the EU added value of cross-country collaboration in the field of CD and the sustainability of the results from JA-CHRODIS and CHRODIS-PLUS beyond 2020, when this project ends, will be approved.
Start date: 01/09/2017 - End date: 30/11/2020

Call: Joint Actions 2016
Topic: Action on chronic diseases
3rd Health Programme (2014-2020)
Joint Action on Tobacco Control [JATC]
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-r...
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-related deaths and illness in the EU consist of the Tobacco Products Directive (TPD), and the WHO Framework Convention on Tobacco Control (FCTC). The TPD lays down rules governing the manufacture, presentation and sale of tobacco and related products. The TPD stipulates that Member States shall require manufacturers and importers of tobacco products to submit to their competent authorities information, via a common entry gate (EU-CEG) – an IT tool designed to ensure uniform application of the reporting and notification obligations, harmonise the submission of data, facilitate comparison and reduce administrative burden.

The general objective of the Joint Action on Tobacco Control will be to provide support for the implementation of the TPD throughout the 28 EU MS through the mining of EU-CEG data, supporting of laboratory collaborations and effort to evaluate priority additives. The specific aims of the project are:

• To ensure appropriate coordination and evaluation
• To support the dissemination of information to the public, regulators and researchers.
• To enhance the ease of access to the data collected through the EU CEG
• To monitor and provide support to the tasks of tobacco and e-cigarette product regulation
• Assist EU MS networking and collaborations between laboratories for tobacco evaluation.
• Support EU MS in the process of monitoring and updating priority additives
• To integrate the JATC results into national policies

With the above in mind, this proposal comes at a perfect timing to aid the regulatory activities that would be needed across the EU MS with regards to the implementation of the TPD across 28 EU MS spanning a population of 508 Million people.
Start date: 16/10/2017 - End date: 15/12/2020

Call: Joint Actions 2016
Topic: Tobacco control